GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Quick Stats
Apr 01, 202651.7
AI Score
HOLD0.37
Volume Ratio
May 12, 2026
Next Earnings
13
+ve Days (30d)
17
-ve Days (30d)
GRAL Stock Summary
Last updated Apr 01, 2026
GRAL is currently trading at $53.6, positioned below its 200-day moving average of $66.07, suggesting bearish momentum. The stock has a 52-week range of $20.44 to $118.84.
Technical Analysis: The 50-day moving average stands at $71.6, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 47.529, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.035, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates GRAL at 51.7/100 with a HOLD recommendation.
GRAL (GRAIL, Inc. Common Stock) Indicators
Last updated Apr 01, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 47.529 |
| CMF (20) | -0.035 |
| ROC (10) | 10.721 |
| ADX (14) | 26.012 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -4.597 |
| AROONOSC (14) | 92.857 |
| WILLAMS %R (14) | -12.726 |
| MFI (14) | 57.236 |
GRAL Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
GRAL Price vs Max Options Open Interest
GRAL Max Change In Options Open Interest
GRAL Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GRAL Daily Out of Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GRAL Daily In the Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GRAL Most Active Options by Volume(near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GRAIL, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
GRAL Moving Averages Analysis
GRAL (GRAIL, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Apr 01, 2026
| Days | MA |
|---|---|
| 10 | 49.82 |
| 20 | 48.7 |
| 30 | 51.39 |
| 50 | 71.6 |
| 100 | 82.78 |
| 200 | 66.07 |
GRAL Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 2.1 billion |
| Earnings/Share ($) | -11.11 |
| Net Proft Margin (%) | -2.7746 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -9.0367 |
| EPS Estimate Next Year ($) | -9.05 |
| WallStreet Target Price ($) | 72.4 |
| Most Recent Quarter |
News Summary: Investors express concerns over $GRAL's valuation and test quality, leading to potential decrease in stock price. Despite recent gains, some believe $GRAL is overvalued and may face further decline. However, others see potential in $GRAL and related companies like $ILMN, $EXAS, and $GH in the future of cancer screening technology.
Updated 2026-02-20 15:00:02